Open an account

Alzamend Neuro

ALZN · NASDAQ

$1.30−$0.03 (−2.26%)TodayMarket closed ·
Prev close $1.33

About ALZN

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing products for the treatment of neurodegenerative and psychiatric disorders. The company is headquartered in Atlanta, Georgia and currently employs 4 full-time employees. The company went IPO on 2021-06-15. The firm is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The firm's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and L-proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient’s immunological system to combat Alzheimer's by removing beta-amyloid from the brain through a royalty-bearing exclusive worldwide license from the Licensor.

Employees
4
Headquarters
Atlanta, Georgia
Listed
Jun 15, 2021
Sector
Health Care
Industry
Biotechnology
Website
alzamend.com

ALZN key statistics

Market cap
6.27M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
58.41K
Volume
10.92K
Open price
$1.30
High today
$1.33
Low today
$1.28
52 Week high
$2.68
52 Week low
$0.84

Alzamend Neuro (ALZN) at a glance

Alzamend Neuro (ALZN) last traded at $1.30, with a market cap of 6.27M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.28 and $1.33. The current price is 1.6% above the day's low and 2.3% below its high.

Volume so far is 10.92K shares, below the average of 58.41K shares a day.

Over the past year Alzamend Neuro has ranged from $0.84 to $2.68, and now sits 25% of the way up that range.

Alzamend Neuro met or beat analyst EPS estimates in 7 of the last 8 quarters. In Q1 FY27 it reported -$0.68 per share against an estimate of -$0.5712.

The average analyst price target is $26.52, 1940.0% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 1 analyst rating say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 3 analystsAvg $26.52
Low
$26.26
Now
$1.30
High
$27.30

ALZN earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 7 of the last 8 quarters, by 56.1% on average.

  1. Q1 FY25: reported -$11.25 per share against an estimate of -$21.85
  2. Q2 FY25: reported -$3.42 per share against an estimate of -$3.49
  3. Q3 FY25: reported -$0.30 per share against an estimate of -$1.99
  4. Q2 FY26: reported -$0.30 per share against an estimate of -$1.99
  5. 2026-03-31: reported -$0.58 per share against an estimate of -$1.96
  6. Q3 FY26: reported -$0.58 per share against an estimate of -$1.96
  7. Q4 FY26: reported -$0.47 per share against an estimate of -$0.6834
  8. Q1 FY27: reported -$0.68 per share against an estimate of -$0.5712

ALZN news

  • Press releasePRNewswire

    Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

  • Press releasePRNewswire

    Alzamend Neuro's Phase 1/2A Lithium Neuroimaging Data Accepted for Poster Presentation at Neuroscience 2026 in Washington, DC

  • Press releasePRNewswire

    Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted for Oral Presentation at ISMRM Workshop on X-Nuclei MR in Barcelona, Spain

  • Press releasePRNewswire

    Alzamend Neuro Announces Initial Closing of Securities Purchase Agreement with Ault Lending

  • Press releasePRNewswire

    Alzamend Neuro Reports Encouraging Pharmacodynamic Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study in a Trial Conducted at Massachusetts General Hospital

  • Press releasePRNewswire

    Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

  • Press releasePRNewswire

    Alzamend Neuro Initiates Phase II Clinical Trial of AL001 "Lithium in Brain" Study in Patients with Bipolar Disorder in Collaboration with Massachusetts General Hospital

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Similar companies

Companies in the same industry as Alzamend Neuro

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.